Case and Research Letters
Topical 0.2% Rapamycin to Treat Facial Angiofibromas and Hypomelanotic Macules in Tuberous Sclerosis
Rapamicina tópica al 0,2% para el tratamiento de angiofibromas faciales y máculas hipomelanóticas en la esclerosis tuberosa
Leído
8446
Vecesse ha leído el artículo
2367
Total PDF
6079
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 37 | 3 | 40 |
| 2025 5 | 225 | 36 | 261 |
| 2025 4 | 217 | 23 | 240 |
| 2025 3 | 145 | 20 | 165 |
| 2025 2 | 168 | 28 | 196 |
| 2025 1 | 152 | 25 | 177 |
| 2024 12 | 101 | 34 | 135 |
| 2024 11 | 118 | 54 | 172 |
| 2024 10 | 96 | 45 | 141 |
| 2024 9 | 110 | 33 | 143 |
| 2024 8 | 156 | 64 | 220 |
| 2024 7 | 111 | 32 | 143 |
| 2024 6 | 77 | 25 | 102 |
| 2024 5 | 85 | 31 | 116 |
| 2024 4 | 90 | 22 | 112 |
| 2024 3 | 69 | 18 | 87 |
| 2024 2 | 52 | 33 | 85 |
| 2024 1 | 60 | 39 | 99 |
| 2023 12 | 76 | 32 | 108 |
| 2023 11 | 91 | 33 | 124 |
| 2023 10 | 60 | 43 | 103 |
| 2023 9 | 78 | 39 | 117 |
| 2023 8 | 70 | 10 | 80 |
| 2023 7 | 87 | 31 | 118 |
| 2023 6 | 72 | 27 | 99 |
| 2023 5 | 113 | 23 | 136 |
| 2023 4 | 91 | 27 | 118 |
| 2023 3 | 57 | 24 | 81 |
| 2023 2 | 68 | 21 | 89 |
| 2022 1 | 62 | 19 | 81 |
| 2022 12 | 90 | 31 | 121 |
| 2022 11 | 39 | 27 | 66 |
| 2022 10 | 48 | 28 | 76 |
| 2022 9 | 61 | 28 | 89 |
| 2022 8 | 38 | 36 | 74 |
| 2022 7 | 25 | 38 | 63 |
| 2022 6 | 30 | 27 | 57 |
| 2022 5 | 94 | 39 | 133 |
| 2022 4 | 98 | 30 | 128 |
| 2022 3 | 89 | 36 | 125 |
| 2022 2 | 80 | 25 | 105 |
| 2021 1 | 60 | 36 | 96 |
| 2021 12 | 50 | 27 | 77 |
| 2021 11 | 59 | 41 | 100 |
| 2021 10 | 78 | 48 | 126 |
| 2021 9 | 80 | 34 | 114 |
| 2021 8 | 77 | 28 | 105 |
| 2021 7 | 67 | 30 | 97 |
| 2021 6 | 51 | 33 | 84 |
| 2021 5 | 74 | 26 | 100 |
| 2021 4 | 210 | 67 | 277 |
| 2021 3 | 102 | 28 | 130 |
| 2021 2 | 102 | 35 | 137 |
| 2020 1 | 71 | 18 | 89 |
| 2020 12 | 33 | 19 | 52 |
| 2020 11 | 24 | 18 | 42 |
| 2020 10 | 32 | 18 | 50 |
| 2020 9 | 42 | 15 | 57 |
| 2020 8 | 37 | 20 | 57 |
| 2020 7 | 37 | 22 | 59 |
| 2020 6 | 44 | 27 | 71 |
| 2020 5 | 36 | 23 | 59 |
| 2020 4 | 24 | 20 | 44 |
| 2020 3 | 38 | 17 | 55 |
| 2020 2 | 5 | 4 | 9 |
| 2020 1 | 4 | 6 | 10 |
| 2019 12 | 8 | 3 | 11 |
| 2019 11 | 4 | 2 | 6 |
| 2019 10 | 3 | 6 | 9 |
| 2019 9 | 9 | 8 | 17 |
| 2019 8 | 4 | 2 | 6 |
| 2019 7 | 2 | 5 | 7 |
| 2019 6 | 6 | 7 | 13 |
| 2019 5 | 2 | 13 | 15 |
| 2019 4 | 0 | 1 | 1 |
| 2019 3 | 2 | 5 | 7 |
| 2019 1 | 1 | 2 | 3 |
| 2018 12 | 0 | 1 | 1 |
| 2018 10 | 3 | 0 | 3 |
| 2018 9 | 1 | 0 | 1 |
| 2018 6 | 0 | 4 | 4 |
| 2018 5 | 0 | 5 | 5 |
| 2018 4 | 0 | 5 | 5 |
| 2018 3 | 1 | 6 | 7 |
| 2018 2 | 42 | 10 | 52 |
| 2018 1 | 78 | 10 | 88 |
| 2017 12 | 40 | 11 | 51 |
| 2017 11 | 40 | 8 | 48 |
| 2017 10 | 50 | 15 | 65 |
| 2017 9 | 34 | 12 | 46 |
| 2017 8 | 39 | 16 | 55 |
| 2017 7 | 28 | 9 | 37 |
| 2017 6 | 38 | 20 | 58 |
| 2017 5 | 26 | 22 | 48 |
| 2017 4 | 25 | 9 | 34 |
| 2017 3 | 23 | 30 | 53 |
| 2017 2 | 19 | 11 | 30 |
| 2016 1 | 18 | 13 | 31 |
| 2016 12 | 35 | 28 | 63 |
| 2016 11 | 43 | 18 | 61 |
| 2016 10 | 35 | 17 | 52 |
| 2016 9 | 1 | 13 | 14 |
| 2016 8 | 0 | 2 | 2 |
| 2016 7 | 8 | 1 | 9 |
| 2016 6 | 5 | 1 | 6 |
| 2016 5 | 10 | 3 | 13 |
| 2016 4 | 17 | 32 | 49 |
| 2016 3 | 12 | 2 | 14 |
| 2016 2 | 15 | 16 | 31 |
| 2015 1 | 9 | 1 | 10 |
| 2015 12 | 21 | 1 | 22 |
| 2015 11 | 16 | 2 | 18 |
| 2015 10 | 13 | 3 | 16 |
| 2015 9 | 8 | 5 | 13 |
| 2015 8 | 17 | 1 | 18 |
| 2015 7 | 28 | 3 | 31 |
| 2015 6 | 21 | 4 | 25 |
| 2015 5 | 22 | 11 | 33 |
| 2015 4 | 11 | 7 | 18 |
| 2015 3 | 13 | 4 | 17 |
| 2015 2 | 9 | 7 | 16 |
| 2015 1 | 11 | 5 | 16 |
| 2014 12 | 9 | 4 | 13 |
| 2014 11 | 8 | 4 | 12 |
| 2014 10 | 13 | 2 | 15 |
Mostrar todo
